Authors' reply to Fralick and Kesselheim

Affiliations

¹ Working Group on Health, Transparency International Germany, and Comprehensive Cancer Centre Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.
² Institute of Epidemiology and Social Medicine, University of Münster, Albert Schweitzer Campus 1, 48149 Münster, Germany.
³ Institute of Public Health, Charité-Universitätsmedizin Berlin, Seestraße 73, 13347 Berlin, Germany.

Comment

Angela Spelsberg et al. BMJ. 2017.

. 2017 Apr 12:357:j1850.

doi: 10.1136/bmj.j1850.

¹ Working Group on Health, Transparency International Germany, and Comprehensive Cancer Centre Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.
² Institute of Epidemiology and Social Medicine, University of Münster, Albert Schweitzer Campus 1, 48149 Münster, Germany.
³ Institute of Public Health, Charité-Universitätsmedizin Berlin, Seestraße 73, 13347 Berlin, Germany.

No abstract available

Comment on

Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.
Spelsberg A, Prugger C, Doshi P, Ostrowski K, Witte T, Hüsgen D, Keil U; Working Group on Health and Working Group on Freedom of Information, Transparency International Deutschland eV. Spelsberg A, et al. BMJ. 2017 Feb 7;356:j337. doi: 10.1136/bmj.j337. BMJ. 2017. PMID: 28174182 Free PMC article.
Three design aspects for high quality post-marketing cohort studies.
Fralick M, Kesselheim AS. Fralick M, et al. BMJ. 2017 Apr 12;357:j1851. doi: 10.1136/bmj.j1851. BMJ. 2017. PMID: 28404570 No abstract available.